staurosporine has been researched along with Mast-Cell Leukemia in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Abdelmagid, MG; Al-Kali, A; Begna, KH; Farrukh, F; Gangat, N; Larsen, JT; Litzow, MR; Pardanani, A; Reichard, KK; Sher, T; Singh, A; Tefferi, A | 1 |
| Cheng, LL; Dai, YT; Fan, LQ; Fang, H; Jiang, L; Liu, F; Liu, H; Liu, MK; Sun, XJ; Wang, L; Weng, XQ; Zhao, WL | 1 |
| Kim, ES | 1 |
| Berube, C; Corless, C; Coutre, S; DeAngelo, DJ; Dutreix, C; George, TI; Gotlib, J; Graubert, TJ; Langford, C; Liedtke, M; Linder, A; Ma, J; Medeiros, B; Merker, JD; Perkins, C; Ruffie, PA; Sternberg, D; Westervelt, P | 1 |
| Arock, M; Berger, D; Bibi, S; Blatt, K; Eisenwort, G; Hadzijusufovic, E; Herrmann, H; Hoermann, G; Hoffmann, T; Horny, HP; Jawhar, M; Moriggl, R; Peter, B; Reiter, A; Schwaab, J; Sotlar, K; Sperr, WR; Stefanzl, G; Valent, P; Willmann, M; Wingelhofer, B; Zuber, J | 1 |
| Chen, PM; Chiou, TJ; Gau, JP; Hong, YC; Hsiao, LT; Liu, CY; Liu, JH; Lu, DY; Tzeng, CH; Yu, YB | 1 |
| Frater, JL; Hassan, A; Kreisel, FH; Xu, X | 1 |
| Akin, C; Awan, FT; George, TI; Gotlib, J; Hartmann, K; Hermine, O; Hexner, E; Horny, HP; Huntsman Labed, A; Kluin-Nelemans, HC; Mauro, MJ; Reiter, A; Sotlar, K; Stanek, EJ; Sternberg, DW; Valent, P; Villeneuve, M | 1 |
| Pardanani, A | 1 |
| Arber, DA; Berubé, C; Chen, CC; Cohen, PS; Coutré, SE; Durocher, JA; Galli, SJ; George, TI; Gilliland, DG; Gotlib, J; Growney, JD; Heinrich, MC; Kajiguchi, T; Lichy, JH; Lilleberg, SL; Neckers, L; Ruan, J; Wang, Y; Williams, C | 1 |
| Aichberger, KJ; Böhm, A; Derdak, S; Fabbro, D; Gleixner, KV; Gruze, A; Manley, PW; Mayerhofer, M; Pickl, WF; Samorapoompichit, P; Sillaber, C; Sonneck, K; Valent, P | 1 |
2 review(s) available for staurosporine and Mast-Cell Leukemia
| Article | Year |
|---|---|
Midostaurin: First Global Approval.
Topics: Adolescent; Adult; Clinical Trials as Topic; Drug Approval; Humans; Leukemia, Mast-Cell; Leukemia, Myeloid, Acute; Mastocytosis, Systemic; Middle Aged; Protein Kinase Inhibitors; Staurosporine; United States; United States Food and Drug Administration; Young Adult | 2017 |
Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management.
Topics: Adrenal Cortex Hormones; Adult; Bone Marrow Examination; Cell Lineage; Cladribine; Clinical Trials as Topic; Clone Cells; Disease Management; Disease Progression; Humans; Hydroxyurea; Immunophenotyping; Interferon-alpha; Leukemia, Mast-Cell; Mast Cells; Mastocytosis, Systemic; Mutation, Missense; Organ Specificity; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Risk Assessment; Staurosporine; Tryptases | 2012 |
2 trial(s) available for staurosporine and Mast-Cell Leukemia
| Article | Year |
|---|---|
Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Leukemia, Mast-Cell; Male; Mastocytosis, Systemic; Middle Aged; Protein Kinase Inhibitors; Staurosporine; Young Adult | 2018 |
Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Leukemia, Mast-Cell; Male; Mastocytosis, Systemic; Middle Aged; Multivariate Analysis; Staurosporine; Survival Analysis; Treatment Outcome | 2016 |
7 other study(ies) available for staurosporine and Mast-Cell Leukemia
| Article | Year |
|---|---|
Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases.
Topics: Aged; Female; Humans; Leukemia, Mast-Cell; Male; Mastocytosis; Mastocytosis, Systemic; Proto-Oncogene Proteins c-kit; Retrospective Studies; Staurosporine | 2022 |
Case Report: Molecular and microenvironment change upon midostaurin treatment in mast cell leukemia at single-cell level.
Topics: Combined Modality Therapy; Humans; Leukemia, Mast-Cell; Male; Mast Cells; Middle Aged; Staurosporine; Tumor Microenvironment | 2023 |
Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.
Topics: Adult; Aged; Aged, 80 and over; Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Dasatinib; Dogs; Drug Resistance, Neoplasm; Drug Synergism; Female; G2 Phase Cell Cycle Checkpoints; Humans; Leukemia, Mast-Cell; Male; Mast Cells; Mastocytosis, Systemic; Middle Aged; Norbornanes; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; STAT5 Transcription Factor; Staurosporine; Tumor Suppressor Proteins; Young Adult | 2018 |
Mast cell leukemia: an extremely rare disease.
Topics: Aged; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Mast-Cell; Male; Piperazines; Pyrimidines; Staurosporine | 2014 |
Mast cell leukemia with prolonged survival on PKC412/midostaurin.
Topics: Aged; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Female; Humans; Leukemia, Mast-Cell; Staurosporine | 2014 |
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.
Topics: Aspartic Acid; Cell Proliferation; Cells, Cultured; Female; Humans; Immunophenotyping; Leukemia, Mast-Cell; Middle Aged; Mutation; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Staurosporine | 2005 |
PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects.
Topics: Anti-Bacterial Agents; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; CD2 Antigens; Cell Proliferation; Cells, Cultured; Cladribine; Down-Regulation; Doxycycline; Drug Evaluation, Preclinical; Drug Interactions; Drug Synergism; Female; Humans; Imatinib Mesylate; Immunophenotyping; In Vitro Techniques; Leukemia, Mast-Cell; Middle Aged; Mutation; Phosphorylation; Piperazines; Platelet Membrane Glycoproteins; Protein Kinase C; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine; Tetraspanin 30 | 2006 |